Subject: Specialised Services Circular (SSC 2678)
Sent on behalf of: Chair of the SW Specialised Service Circular Group

Dear Colleagues,

Please find attached the following Specialised Services Circular(s):

SSC Number	SSC Title	Trusts approved to prescribe in accordance with the SSC, providing appropriate internal governance arrangements are in place
2678	NICE Technology Appraisal Draft Guidance: Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy	• All South West Acute Providers

Is an implementation plan required for this SSC? NO

For all other SouthWest region trusts this is for information only.

Trusts should ensure that use is registered on the Blueteq system (if appropriate).

Treatment will only be funded where the drugs minimum dataset is fully and accurately populated.

Please direct any queries to: england.speccomm-southwest@nhs.net

Specialised Commissioning
South West
NHS England
360 Bristol
Marlborough Street
Bristol
BS1 3NX
Email: england.speccomm-southwest@nhs.net

4 July 2024

All Chief Executives

All Medical Directors

All Chief Pharmacists

Re: NICE Technology Appraisal Draft Guidance: Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy

I am writing to advise you regarding the funding position on the recently published NICE Technology Appraisal Draft Guidance (DG) for rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy.

The DG can be found at: https://www.nice.org.uk/guidance/indevelopment/gid-ta10999.

NICE in their DG published on 8 July 2024 has stated that:

> Rucaparib is recommended as an option for the maintenance treatment of advanced (International Federation of Gynaecology and Obstetrics [FIGO] stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer after complete or partial response to first-line platinum-based chemotherapy in adults, only if:
> - it is homologous recombination deficiency (HRD) positive, and
> - BRCA mutation-negative,

Rucaparib will be available via the Cancer Drugs Fund (CDF) from 8 July 2024 in line with these recommendations and according to a set of treatment criteria which translates the NICE recommendation into a clinical guide as to use in practice. These treatment criteria can be found on the national CDF list at https://www.england.nhs.uk/cancer/cdf/cancer-drugs-fund-list/ or on the application

form(s) on the Blueteq site.

NHS England will then routinely commission rucaparib in patients with advanced ovarian, fallopian tube and peritoneal cancer, incorporating these treatment criteria, including those contained within this letter from 90 days after the day of publication of the final guidance.

In addition:

- Trusts must ensure that they are purchasing rucaparib at the agreed proposed patient access scheme (PAS) discounted price. This discounted price will be applied automatically at point of invoice and applies to all indications. Trusts should refer to the CAP portal for further information on the PAS price. The CAP portal is available at https://nhsengland.sharefile.eu/Authentication/Login
- Trusts must ensure that, until 90 days after publication of the final guidance from NICE, only invoices for the drug procurement costs of rucaparib in this indication are directed to the CDF and that they are also submitting complete and accurate information via the CDF minimum dataset (MDS).
- In line with the terms and conditions included in the NHS Standard Contract and as per the agreement that Cancer Services are commissioned with Trusts, Schedule 6a Reporting Requirements for drugs will apply. Payment of Trust invoices will be contingent on the completion of the MDS record and this information being made available in a timely way.
- Trusts must ensure they are registering rucaparib use on SACT. The SACT dataset is a mandated dataset as part of the Health and Social Care Information Standards. This is listed as a Schedule 6 national information requirement within the NHS Standard Contract.
- Patients must be registered via Blueteq (RUC3) and meet the clinical criteria on the registration form during the interim funding period.
- **Payment of Trust invoices will be contingent on Blueteq registration, the full SACT and CDF MDS record applicable to the drug being completed and this information being made available in timely way.**
- Trusts must ensure that local governance aspects (e.g. technical issues, education & training, patient information) have been identified and addressed for all staff groups (as appropriate) in order to permit the safe delivery of this therapy.

I would be grateful if you could cascade this information to relevant clinical teams within your organisation to support the consistent adoption of the policy nationally.

Yours sincerely,

Luke Culverwell

Deputy Director of Specialised Commissioning

Tracey Williams

Principle Pharmacist